Supplier Quality Engineer 2

Orthofix Medical stock sits 41.79 percent below its yearly high with USD 399.8 million value. Published on 10/20/2026 at 20:23 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS Orthofix Medical had USD 399.8 million in market value on October 20, 2026. Orthofix Medical stock costs EUR 8.83 on October 20, 2026. Market facts at a glance. * Orthofix Medical had a USD 399.8 million market capitalization on October 20, 2026. * Five analysts held a consensus Hold rating with a USD 14.75 average target on October 11, 2026. * Orthofix Medical stock costs EUR 8.83 at Lang & Schwarz on October 20, 2026 at 8:14 p.m. CEST. Orthofix Medical (ISIN US68752M1080) had a USD 399.8 million market capitalization on October 20, 2026, while its Nasdaq-listed stock remained a small-cap medical technology name. The company develops spinal implants, biologics, limb reconstruction systems and enabling technologies for musculoskeletal care, according to its Orthofix Medical investor-relations page. Orthofix Medical was trading at EUR 8.83 at Lang & Schwarz on October 20, 2026 at 8:14 p.m. CEST. Discover more Invest in Stocks Analysts see a higher target. MarketBeat reported on October 11, 2026 that five analysts had a consensus Hold rating for Orthofix Medical. The group included three buy ratings, one hold and one sell, with an average 12-month target of USD 14.75, according to MarketBeat. The target was above the recent USD 9.17 share price cited in that report, but the mixed rating distribution shows that the valuation case is not uniform. Stock remains near its yearly floor. The latest structured quote put OFIX at USD 9.89 on October 20, 2026 at 2:22 p.m. ET, with a USD 8.50 to USD 16.99 52-week range and 154,030 shares traded. The current quote was USD 1.10 above the yearly low and USD 7.10 below the yearly high. These levels place the stock closer to the lower end of its annual trading band than to its high. Quarterly losses remain relevant. Orthofix reported USD 210.93 million of revenue and a USD 0.39 adjusted loss per share for the second quarter of 2026, compared with a USD 209.28 million revenue consensus and a USD 0.40 expected loss, according to Investing.com. The same report said the company raised its full-year 2026 sales and adjusted EBITDA guidance after reimbursement and distribution developments. What the valuation leaves open. The central contrast is between the USD 14.75 analyst target and the latest USD 9.89 Nasdaq quote. Orthofix also carried USD 873.0 million of total assets at June 30, 2026, while operating cash flow was negative USD 6.2 million in the second quarter of 2026. That combination leaves profitability and cash generation as important measures for the next reported period. Discover more Read Economics Explore Exchanges Trade Derivatives Orthofix Medical stock in euros. Orthofix Medical was trading at EUR 8.83 at Lang & Schwarz on October 20, 2026 at 8:14 p.m. CEST. The further course of trading is shown by the continuously updated real-time quote of Orthofix Medical stock. Orthofix Medical at a glance. * Company: Orthofix Medical Inc. * ISIN: US68752M1080 * Ticker: OFIX * Primary exchange: Nasdaq * Price Lang & Schwarz (as of October 20, 2026, 8:14 p.m. CEST): EUR 8.83 * Market capitalization: USD 399.8 million (as of October 20, 2026) * 52-week range: USD 8.50-16.99 (as of October 20, 2026) * Sector / Industry: Health Care / Medical Devices Sponsored Ad Orthofix Medical stock: new analysis - 21 October. Discover more Source Med Gear Read Company News Find Surgeons Fresh Orthofix Medical information released. What's the impact for investors? Our latest independent report examines recent figures and market trends. Disclaimer regarding our articles: This is not investment advice, nor is it a recommendation to buy or sell. Information regarding prices, companies, and markets is provided without guarantee; changes may occur at any time. Stock market transactions can result in significant losses. Our articles are created and reviewed, in whole or in part, automatically with the assistance of AI. en | US68752M1080 | OFIX | boerse | 70377301 | bgmi

North America leads Foot and Ankle Reconstruction devices market. Foot and ankle problems don't get the attention that hip and knee replacements do, but the devices used to fix them - plates, screws, fusion systems, total ankle implants - are quietly becoming one of the more dynamic corners of orthopedics. Here's where the market stands and where it's headed. Market Size and Growth Metrics The global foot and ankle reconstruction devices market was valued at USD 1.8 billion in 2025 and is estimated to reach USD 1.9 billion in 2026. From there, it's projected to climb to USD 3.3 billion by 2033, growing at a CAGR of 8.3% between 2026 and 2033 - nearly doubling in under a decade. What's fueling that growth: * An aging population with degenerative joint disease. The CDC estimated roughly 33 million U.S. adults were living with osteoarthritis by the end of 2024, and the Osteoarthritis Action Alliance projects that figure will hit 72 million by 2030 and 78 million by 2040. Around 25% of ankle fractures in patients over 60 are linked to osteoporosis, and ankle osteoarthritis affects an estimated 3.4% of the global adult population - all of which translates into steady surgical demand. * Minimally invasive techniques going mainstream. Surgeons are shifting toward smaller incisions, faster recovery, and procedure-specific instrumentation for tendon repairs, fusions, and osteotomies. * Smarter surgical technology. Computer-assisted navigation, AI-driven imaging interpretation, and predictive planning tools are improving implant placement accuracy and reducing revision rates. By the numbers: * North America led all regions with a 47.9% revenue share in 2025, backed by strong reimbursement systems and high procedure volumes; the U.S. is the largest single country market. * Hallux valgus (bunion) correction was the top application segment at 31.4% share in 2025, though hammertoe correction is expected to grow fastest through the forecast period. * Hospitals captured 59.7% of end-use revenue in 2025, while outpatient/ambulatory surgical centers are the fastest-growing setting, as more elective reconstruction procedures move out of inpatient settings entirely. One notable headwind: regulatory complexity. Compliance with FDA requirements, EU MDR 2017/745, and region-specific approval pathways adds significant time and cost to bringing new implants to market - a burden that falls hardest on smaller manufacturers. Competitive Landscape and Core Players The market splits fairly cleanly into two tiers. Established multinational players - Stryker, DePuy Synthes (Johnson & Johnson), Zimmer Biomet, Smith+Nephew, and Arthrex - compete on scale: broad product portfolios spanning trauma, reconstruction, and sports medicine; deep clinical evidence; global distribution; and long-standing surgeon relationships. Their weakness is largely structural - premium pricing and complex regulatory overhead can limit adoption in cost-sensitive settings. Emerging and specialized players - Globus Medical, Orthofix, Enovis, Acumed, CONMED, and Anika Therapeutics - compete on agility, focusing on procedure-specific fixation systems, orthobiologics, and minimally invasive implants. They move faster on niche innovation but lack the global footprint and hospital procurement relationships of the majors. Recent activity shows both tiers pushing hard on product launches: * Stryker expanded its Foot & Ankle portfolio in the U.S. (September 2024) with the Osteotomy Truss System and Ankle Truss System for fusion and total ankle procedures. * DePuy Synthes launched the TriLEAP Lower Extremity Anatomic Plating System (August 2025) for forefoot and midfoot reconstruction. * Zimmer Biomet and Treace Medical Concepts both showcased updated bunion-correction and total ankle systems at the AOFAS Annual Conference in September 2025. * Fusion Orthopedics acquired Metalogix External Fixation Systems (January 2025), adding external fixation frames and mini-rail systems to its lineup - a sign that M&A activity, while moderate overall, is still reshaping portfolios. Competitive advantage increasingly hinges on demonstrable clinical outcomes and comprehensive, procedure-specific offerings that bundle implants, biologics, and digital surgical planning together, rather than any single device. Product Specifications and Innovation Highlights Reconstruction devices in this market are segmented by the specific anatomical problem they solve. Hallux Valgus/Bunion Correction devices include plates, screws, staples, and intramedullary fixation and osteotomy implants, all designed to realign the first metatarsal and great toe. Hammertoe Correction relies on intramedullary implants, fixation pins, screws, and fusion systems to realign and stabilize the affected interphalangeal joints. Midfoot Reconstruction uses fusion plates, locking screws, and compression staples to stabilize the tarsometatarsal and naviculocuneiform joints following trauma, arthritis, or Charcot foot. Hindfoot & Ankle Reconstruction devices - arthrodesis plates, intramedullary nails, locking screws, and compression systems - restore alignment and stability in severe arthritis, instability, or post-traumatic cases. Total Ankle Replacement (TAR) implants use prosthetic tibial and talar components to replace the damaged joint while preserving natural motion, offering an alternative to fusion for end-stage arthritis. Toe Joint Replacement systems, primarily targeting the first metatarsophalangeal (MTP) joint, use artificial joint implants to restore mobility and relieve pain in arthritic or degenerated toes. Some recent product specifics worth noting: * SINTX Technologies' SINAPTIC Foot & Ankle Osteotomy Wedge System (FDA-cleared October 2025) is made from silicon nitride, engineered specifically for hallux valgus precision. * Medline UNITE's REFLEX HYBRID Nitinol Implant System (FDA 510(k), April 2025) combines locking plate stability with nitinol staple compression for MTP fusions and Lapidus procedures. * Forma Medical's OptimalHT system (2023) brought dedicated minimally invasive instrumentation to hammertoe correction, a segment that had lagged behind bunion surgery in MIS adoption. * NovaBone's bioglass syringes (2.5cc/5cc) target bone defect repair and osseointegration as an adjunct to hardware-based fixation. The throughline across nearly every recent launch is anatomical specificity paired with less invasive delivery - implants engineered for one exact procedure rather than general-purpose hardware, combined with smaller incisions and faster weight-bearing timelines. This market rewards companies that can pair strong clinical data with genuinely differentiated, procedure-specific hardware - a pattern likely to hold as the patient population driving demand (older, more diabetic, more active later in life) continues to grow. Customize This Report - get 20% free customization to tailor scope, segments, or regions to your needs Matched content.